by Lori Solomon The U.S. Food and Drug Administration has approved Merck’s Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. Capvaxive is specifically designed to help protect adults against the serotypes that cause the majority of invasive pneumococcal disease cases, including Streptococcus pneumoniae serotypes 3, 6A,...
Category: <span>Pharmaceutical Updates</span>
Post
FDA expands pediatric indication for Rinvoq
by Lori Solomon The U.S. Food and Drug Administration has expanded indications for AbbVie’s Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA). Rinvoq is indicated for pediatric patients with an inadequate response or intolerance to one or more tumor necrosis factor...
Post
New study finds medication abortion without ultrasound to be safe
JUNE 24, 2024 by University of California, San Francisco Credit: Unsplash/CC0 Public DomainResearchers compared patients who received care remotely to those who got ultrasounds and found no differences in outcomes. Medication abortion patients who receive pills by mail without first getting an ultrasound do just as well as those who are examined and given the...
Post
Tirzepatide Significantly Reduces Sleep Disruptions
Medscape Medical News > Conference News > ADA 2024 Alicia Ault June 22, 2024s ORLANDO, Fla. — The diabetes and weight loss drug tirzepatide (Mounjaro for type 2 diabetes; Zepbound for obesity) was so effective at reducing sleep disruptions in patients with obesity and obstructive sleep apnea (OSA) that 40% to 50% no longer needed...
Post
Exploring the antidepressant effects of oleacein, a rare compound found in olives
JUNE 25, 2024 by University of Tsukuba Summary of the evidence on potential neurogenesis-promoting and neuroinflammation-mitigating effects of oleacein. Credit: Cell Communication and Signaling (2024). DOI: 10.1186/s12964-024-01691-xResearchers are exploring natural compounds as potential alternatives to conventional antidepressants, which often yield inconsistent results. Compounds that activate the TrkB receptor are of particular interest, as this receptor...
Post
Trial offers hope for cheaper, more tolerable, ketamine treatment
JUNE 24, 2024 by University of Otago Credit: Unsplash/CC0 Public DomainFor those suffering from treatment-resistant depression, the anesthetic drug ketamine offers hope, but it has side effects and can be costly to access—a University of Otago-led clinical trial may change that. Working in collaboration with New Zealand’s Douglas Pharmaceuticals, researchers have conducted a trial of...
Post
BLUE CHEESE COMPOUND MAY FIGHT CANCER
JUNE 24TH, 2024POSTED BY MAX ESTERHUIZEN-VIRGINIA TECH(Credit: Towfiqu barbhuiya/Unsplash) TAGS : BACTERIA, CANCER, FOOD, MOLDUNIVERSITY : VIRGINIA TECH Researchers have discovered a way to synthesize a compound in the mold of blue cheese that has antibacterial and anticancer properties. The marbled veins of blue cheese, which are edible Penicillium molds, produce compounds with antifungal, antibacterial,...
Post
FDA panel OKs new COVID vaccine for fall
JUNE 6, 2024 by Robin Foster A U.S. Food and Drug Administration advisory panel on Wednesday recommended updating the formula for COVID vaccines ahead of a fall campaign that will encourage Americans to get the latest shots. The unanimous vote recommends that vaccine makers tailor the next vaccine to target the JN.1 variant, which dominated...
Post
New Oral Weight Loss Drugs: Where Are We and What’s Next?
Medscape Medical News > Features Marilynn Larkin June 05, 2024 Now that semaglutide (Wegovy), tirzepatide (Zepbound), and other injectables have created an insatiable market for weight loss drugs, biotech and pharmaceutical companies are roaring ahead with oral formulations, which promise a greater level of convenience, in line with patient preference. One particularly intriguing entry is...
Post
Developing Drugs for Neurodegenerative Diseases
By Matthew AdamsReviewed by Danielle Ellis, B.Sc.Understanding neurodegenerative diseasesCurrent treatment landscapeEmerging therapeutic strategiesRole of technology and AIChallenges in drug developmentEthical and regulatory considerationsFuture directionsConclusionReferencesFurther reading Neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease significantly impact the health of many people worldwide. Due to this impact, researchers around the globe are collaborating to develop targeted treatments....